An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

The Lancet Diabetes & Endocrinology, dedicated to covering the disciplines of diabetes, endocrinology, and metabolism, is the latest title in The Lancet family of specialty journals. Continuing in ...

Lancets play an integral part in glucose monitoring for diabetes management as single-use designs help ensure safety and hygiene thereby decreasing risks of infections or cross-contamination ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

In 2004 a young child took ~20 lancets for diabetic use into a primary school. The lancets became scattered in an outdoor play area. Several children between 5 and 10 years of age found and played ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

About a quarter of the 828 million adults globally living with diabetes — either type 1 or 2 — are in India, a paper published in The Lancet said on Wednesday. Apart from the 212 million ...